Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled study of inhaled esketamine for treatment-resistant depression
2018-001963-22Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing Inhaled esketamine with Placebo (2 arms). Primary endpoint: Change from baseline in MADRS total score at Day 14. Started Jun 2018; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-001963-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001963-22.